.png){kind=icon}
返回
S
Stephen V. Liu
georgetown university
55H指数
780论文数
1.9W被引数
收录论文 160
发表时间
.png){kind=icon}
.png){kind=icon}
PP01.144: Patient-Reported Outcomes (PROs) from IMforte: A Phase 3 Study of First-Line Maintenance Treatment with Lurbinectedin + Atezolizumab Versus Atezolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)PP01.144: 来自IMforte研究的患者报告结局（PROs）：一项针对广泛期小细胞肺癌（ES-SCLC）患者使用鲁比卡丁+阿替利珠单抗与阿替利珠单抗作为一线维持治疗的III期研究.png)
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏PP01.58: A Global Phase 2/3, Randomized, Open-Label Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) in Combination with Chemotherapy in First-Line (1L) Non-Small Cell Lung Cancer (NSCLC) – ROSETTA Lung-02PP01.58：一项全球性II/III期、随机、开放标签试验，评估Pumitamig（BNT327/BMS986545；PD-L1 × VEGF-A 双特异性抗体）联合化疗在一线（1L）非小细胞肺癌（NSCLC）中的疗效——ROSETTA Lung-02
PREAI
分享收藏Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in
STK11, KEAP1
, or
KRAS
: the TRITON studyRATIONALE AND DESIGN FOR A PHASE IIIb TRIAL OF FIRST-LINE TREMELIUMIMAB PLUS DURVALUMAB VERSUS PEMBROLIZUMAB, IN COMBINATION WITH CHEMOTHERAPY, IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL-CELL LUNG CANCER AND MUTATIONS OR CO-MUTATIONS IN
STK11, KEAP1
, OR
KRAS
: THE TRITON STUDY的中文翻译为：
RATIONALE AND DESIGN FOR A PHASE IIIb TRIAL OF FIRST-LINE TREMELIUMIMAB PLUS DURVALUMAB VERSUS PEMBROLIZUMAB, IN COMBINATION WITH CHEMOTHERAPY, IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL-CELL LUNG CANCER AND MUTATIONS OR CO-MUTATIONS IN
STK11, KEAP1
, OR
KRAS
: THE TRITON STUDY
OAAI
OAAI分享收藏